Editorial: Immunotherapy and multimodality therapy for lung cancer

Chenghu Song; Weici Liu; Yuan Wan; Wenjun Mao

doi:10.3389/fimmu.2024.1372513

Editorial: Immunotherapy and multimodality therapy for lung cancer

Front Immunol. 2024 Jan 26:15:1372513. doi: 10.3389/fimmu.2024.1372513. eCollection 2024.

Authors

Chenghu Song^#¹, Weici Liu^#¹, Yuan Wan², Wenjun Mao¹

Affiliations

¹ Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi People's Hospital, Wuxi Medical Center, Nanjing Medical University, Wuxi, Jiangsu, China.
² The Pq Laboratory of BiomeDx/Rx, Department of Biomedical Engineering, Binghamton University, Binghamton, NY, United States.

^# Contributed equally.

No abstract available

Keywords: immune checkpoint inhibitors; immunotherapy; lung cancer; multimodality therapy; predictive biomarker.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Carcinoma, Non-Small-Cell Lung* / therapy
Combined Modality Therapy
Humans
Immunotherapy
Lung Neoplasms* / therapy

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Natural Science Foundation of Jiangsu Province (BK20210068), the Top Talent Support Program for Young and Middle-aged People of Wuxi Health Commission (BJ2023014, HB2020003), the Mega-project of Wuxi Commission of Health (Z202216), and the General Program of Wuxi Medical Center of Nanjing Medical University (WMCG202305).